Exact Sciences

Privia Health

Exact Sciences' Colorectal Cancer Screening Initiative Sees Success, Undervalued Shares

Abbott Laboratories

Exact Sciences Shareholders Approve Merger with Abbott, Merger to Move Forward

Exact Sciences stockholders approve Abbott merger, reject executive pay proposal.

Abbott to raise $20B via bond sale for Exact Sciences acquisition

Abbott Laboratories Initiates $21 Billion Bond Sale for Exact Sciences Acquisition.

Catalyst<ul> <li>Small and Medium order size fund flows show positive inflow trends indicating increasing retail and mid-sized institutional interest in EXAS.</li></ul>Risk<ul> <li>Two recent Hanging Man patterns signal potential bearish bias while RSI Overbought conditions suggest limited upside momentum.</li> <li>Fundamental analysis notes negative factors including poor gross profit margin and PB-ROE ratios signaling valuation and profitability concerns.</li></ul>

Key Factors

Exact Sciences (EXAS) reported a successful colorectal cancer screening initiative through its collaboration with Amalgam Rx and Privia Health, using EHR-integrated outreach and Cologuard tests to exceed national benchmarks.

Recent Updates

EXAS News